LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Elenco Azioni・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Chiusa

SettoreSettore sanitario

11.94 0.42

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

11.22

Massimo

11.96

Metriche Chiave
By Trading Economics
Entrata	227M
Vendite	139M
P/E Media del settore	4.506 49.701
Margine di Profitto	163.843
Dipendenti	1,796
EBITDA	1.3M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+66.81% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	2.1B
Apertura precedente	11.52
Chiusura precedente	11.94

Notizie sul Sentiment di mercato

By Acuity

10%

90%

9 / 345 Classifica in Healthcare

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 mag 2026, 16:33 UTC

Utili

I principali Market Mover

Webull Shares Slide on 1Q Loss, Soaring Costs

22 mag 2026, 21:10 UTC

Utili

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

22 mag 2026, 19:47 UTC

Utili

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 mag 2026, 19:17 UTC

Discorsi di Mercato

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 mag 2026, 19:10 UTC

Discorsi di Mercato

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 mag 2026, 18:54 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

22 mag 2026, 18:54 UTC

Discorsi di Mercato

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 mag 2026, 18:38 UTC

Discorsi di Mercato

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 mag 2026, 18:35 UTC

Acquisizioni, Fusioni, Takeovers

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 mag 2026, 18:09 UTC

Discorsi di Mercato

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 mag 2026, 17:58 UTC

Discorsi di Mercato

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22 mag 2026, 17:54 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

22 mag 2026, 17:54 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

22 mag 2026, 17:54 UTC

Discorsi di Mercato

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22 mag 2026, 17:03 UTC

Discorsi di Mercato

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22 mag 2026, 16:54 UTC

Discorsi di Mercato

Crypto Spot Volumes Fall 14% in April -- Market Talk

22 mag 2026, 16:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

22 mag 2026, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

22 mag 2026, 16:20 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

22 mag 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

22 mag 2026, 16:16 UTC

Discorsi di Mercato

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22 mag 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

22 mag 2026, 15:55 UTC

Discorsi di Mercato

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22 mag 2026, 15:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

22 mag 2026, 15:42 UTC

Discorsi di Mercato

Oil Continues as Leading Indicator for All Markets -- Market Talk

22 mag 2026, 15:35 UTC

Discorsi di Mercato

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

66.81% in crescita

Previsioni per 12 mesi

Media 20 USD 66.81%

Alto 20 USD

Basso 20 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

9 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.